This settlement involves claims that certain manufacturers and distributors of sartan-based blood pressure medications—such as valsartan, losartan, and irbesartan—sold products contaminated with potentially harmful impurities.
The lawsuit alleges that these medications were distributed despite containing substances like NDMA or NDEA, which are classified as probable human carcinogens. Defendants deny wrongdoing but agreed to a settlement to resolve the claims.
The settlement covers generic versions of sartan medications sold in the United States. These drugs are commonly prescribed to treat high blood pressure and heart conditions.
This settlement matters because it provides compensation to consumers who purchased affected medications and may have paid out-of-pocket costs for drugs later subject to recalls.
Consumers may qualify if they purchased certain generic sartan medications during the specified class period. Eligible products typically include:
• Valsartan
• Losartan
• Irbesartan
• Combination drugs containing these ingredients
Payouts are generally based on the amount spent on eligible medications and may be calculated on a pro-rata basis depending on the number of valid claims submitted and available settlement funds.
FAQ
1. What medications are included in the settlement?
Generic valsartan, losartan, irbesartan, and related combination medications are included.
2. Do I qualify if I had insurance?
You may still qualify, but reimbursement may depend on out-of-pocket costs.
3. How much can I receive?
Payments vary and are typically pro-rata based on your purchases and total claims filed.
4. Do I need receipts?
Documentation may be required to support your claim, depending on the claim type.
5. Can I file a claim online?
Yes, claims can be submitted through the official settlement website.